Citigroup
BBIO icon

Citigroup’s BridgeBio Pharma BBIO Stock Holding History

Citigroup’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.6M Buy
196,000
+15,000
+8% +$1.05M ﹤0.01% 1355
2026
Q1 		$13.4M Buy
+181,000
New +$13.1M 0.01% 1292
2025
Q1 		– Sell
-40,000
Closed -$1.1M – 5587
2024
Q4 		$1.1M Buy
+40,000
New +$1.03M ﹤0.01% 3294
2024
Q2 		– Sell
-29,900
Closed -$925K – 5578
2024
Q1 		$925K Hold
29,900
– – ﹤0.01% 3092
2023
Q4 		$1.21M Buy
29,900
+1,500
+5% +$45K ﹤0.01% 2666
2023
Q3 		$749K Buy
+28,400
New +$806K ﹤0.01% 2748
2022
Q4 		– Sell
-39,100
Closed -$389K – 5774
2022
Q3 		$389K Buy
+39,100
New +$406K ﹤0.01% 3415

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Citigroup's BBIO Position: Q2 2026 in Review

Citigroup increased its BridgeBio Pharma (BBIO) stake by 16% in Q2 2026, buying an estimated $8.24M and bringing the position to 864,101 shares worth $64.4M. The position accounts for 0.02% of the portfolio, ranked #635.

Citigroup first reported a position in BBIO in Q3 2019 and has held it in 28 quarters since. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Citigroup held 864,101 shares of BridgeBio Pharma worth $64.4M as of Q2 2026.
  • Citigroup bought 117,618 BridgeBio Pharma shares in Q2 2026, an estimated $8.24M.
  • BridgeBio Pharma made up 0.02% of Citigroup's portfolio in Q2 2026, its #635 holding.
  • Citigroup first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 28 quarters since.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.